Cargando…

Can Voluntary Health Insurance for Non-reimbursed Expensive New Treatments Be Just?

Public healthcare systems are increasingly refusing (temporarily) to reimburse newly approved medical treatments of insufficient or uncertain cost-effectiveness. As both patient demand for these treatments and their list prices increase, a market might arise for voluntary additional health insurance...

Descripción completa

Detalles Bibliográficos
Autores principales: Smids, Jilles, Bunnik, Eline M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401491/
https://www.ncbi.nlm.nih.gov/pubmed/37547913
http://dx.doi.org/10.1093/phe/phad015
_version_ 1785084676439801856
author Smids, Jilles
Bunnik, Eline M
author_facet Smids, Jilles
Bunnik, Eline M
author_sort Smids, Jilles
collection PubMed
description Public healthcare systems are increasingly refusing (temporarily) to reimburse newly approved medical treatments of insufficient or uncertain cost-effectiveness. As both patient demand for these treatments and their list prices increase, a market might arise for voluntary additional health insurance (VHI) that covers effective but (very) expensive medical treatments. In this paper, we evaluate such potential future practices of VHI in public healthcare systems from a justice perspective. We find that direct (telic) egalitarian objections to unequal access to expensive treatments based on different ability to afford VHI do not stand up to scrutiny. However, such unequal access might lead to loss of self-respect among individuals, or loss of fraternity within society, rendering it more difficult for citizens to interact on equal moral footing. This would be problematic from a relational egalitarian perspective. Moreover, the introduction of VHI might turn out to have negative consequences for the comprehensiveness and/or the quality of the public healthcare services that are offered to all patients equally through basic health insurance. These consequences must be weighed against potential health gains and the value of liberty. We conclude that governments should be careful when considering the introduction of VHI in public healthcare systems.
format Online
Article
Text
id pubmed-10401491
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-104014912023-08-05 Can Voluntary Health Insurance for Non-reimbursed Expensive New Treatments Be Just? Smids, Jilles Bunnik, Eline M Public Health Ethics Original Articles Public healthcare systems are increasingly refusing (temporarily) to reimburse newly approved medical treatments of insufficient or uncertain cost-effectiveness. As both patient demand for these treatments and their list prices increase, a market might arise for voluntary additional health insurance (VHI) that covers effective but (very) expensive medical treatments. In this paper, we evaluate such potential future practices of VHI in public healthcare systems from a justice perspective. We find that direct (telic) egalitarian objections to unequal access to expensive treatments based on different ability to afford VHI do not stand up to scrutiny. However, such unequal access might lead to loss of self-respect among individuals, or loss of fraternity within society, rendering it more difficult for citizens to interact on equal moral footing. This would be problematic from a relational egalitarian perspective. Moreover, the introduction of VHI might turn out to have negative consequences for the comprehensiveness and/or the quality of the public healthcare services that are offered to all patients equally through basic health insurance. These consequences must be weighed against potential health gains and the value of liberty. We conclude that governments should be careful when considering the introduction of VHI in public healthcare systems. Oxford University Press 2023-07-16 /pmc/articles/PMC10401491/ /pubmed/37547913 http://dx.doi.org/10.1093/phe/phad015 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Smids, Jilles
Bunnik, Eline M
Can Voluntary Health Insurance for Non-reimbursed Expensive New Treatments Be Just?
title Can Voluntary Health Insurance for Non-reimbursed Expensive New Treatments Be Just?
title_full Can Voluntary Health Insurance for Non-reimbursed Expensive New Treatments Be Just?
title_fullStr Can Voluntary Health Insurance for Non-reimbursed Expensive New Treatments Be Just?
title_full_unstemmed Can Voluntary Health Insurance for Non-reimbursed Expensive New Treatments Be Just?
title_short Can Voluntary Health Insurance for Non-reimbursed Expensive New Treatments Be Just?
title_sort can voluntary health insurance for non-reimbursed expensive new treatments be just?
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401491/
https://www.ncbi.nlm.nih.gov/pubmed/37547913
http://dx.doi.org/10.1093/phe/phad015
work_keys_str_mv AT smidsjilles canvoluntaryhealthinsurancefornonreimbursedexpensivenewtreatmentsbejust
AT bunnikelinem canvoluntaryhealthinsurancefornonreimbursedexpensivenewtreatmentsbejust